{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:32Z","timestamp":1791375332155,"version":"4.3.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.exphem.2024.104673","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:49:35Z","timestamp":1731689375000},"page":"104673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["FT-4202, a selective pyruvate kinase R activator for sickle cell disease"],"prefix":"10.1016","volume":"141","author":[{"given":"Anna","family":"Ericsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9589-3272","authenticated-orcid":false,"given":"Erik","family":"Wilker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"David R.","family":"Lancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Fessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Troccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Toms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dinsmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans A.","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-2018","authenticated-orcid":false,"given":"Sandra","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-5559","authenticated-orcid":false,"given":"Douglas","family":"Marcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keertik","family":"Fulzele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ribadeneira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1143-2805","authenticated-orcid":false,"given":"Sylvie M.","family":"Guichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2024.104673_bib0001","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/blood-2005-04-1622","article-title":"The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis","volume":"106","author":"van Wijk","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104673_bib0002","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1074\/jbc.M115.676270","article-title":"Conformational dynamics and allostery in pyruvate kinase","volume":"291","author":"Donovan","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2024.104673_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000474982","article-title":"Erythrocyte pyruvate kinase deficiency. The influence of physiologically important metabolites on the function of normal and defective enzymes","volume":"48","author":"Lakomek","year":"1994","journal-title":"Enzyme Protein"},{"key":"10.1016\/j.exphem.2024.104673_bib0004","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2044.1977.tb10002.x","article-title":"Red cell 2,3-diphosphoglycerate and oxygen affinity","volume":"32","author":"MacDonald","year":"1977","journal-title":"Anaesthesia"},{"key":"10.1016\/j.exphem.2024.104673_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228399","article-title":"Sickle cell disease: a distinction of two most frequent genotypes (HbSS and HbSC)","volume":"15","author":"da Guarda","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2024.104673_bib0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.exphem.2024.104673_bib0007","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1537-2995.1980.20681057159.x","article-title":"Viability and function of stored sickle erythrocytes","volume":"20","author":"Castro","year":"1980","journal-title":"Transfusion"},{"key":"10.1016\/j.exphem.2024.104673_bib0008","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1172\/JCI106294","article-title":"Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia","volume":"49","author":"Charache","year":"1970","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2024.104673_bib0009","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1246-7820(96)80001-2","article-title":"Assessment of qualitative functional parameters of stored red blood cells from donors with sickle cell trait (AS) or with heterozygote (AC) status","volume":"3","author":"Ould Amar","year":"1996","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.exphem.2024.104673_bib0010","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood.V85.11.3289.bloodjournal85113289","article-title":"Antisickling effects of 2,3-diphosphoglycerate depletion","volume":"85","author":"Poillon","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104673_bib0011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/iub.15","article-title":"Allosteric properties of hemoglobin and the plasma membrane of the erythrocyte: new insights in gas transport and metabolic modulation","volume":"60","author":"De Rosa","year":"2008","journal-title":"IUBMB Life"},{"key":"10.1016\/j.exphem.2024.104673_bib0012","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2141.2003.04781.x","article-title":"Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells","volume":"124","author":"Banerjee","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2024.104673_bib0013","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4103\/2319-4170.132910","article-title":"ATP, an extracellular signaling molecule in red blood cells: a messenger for malaria?","volume":"37","author":"Ramdani","year":"2014","journal-title":"Biomed J"},{"key":"10.1016\/j.exphem.2024.104673_bib0014","doi-asserted-by":"crossref","first-page":"15320","DOI":"10.1073\/pnas.0904614106","article-title":"ATP-dependent mechanics of red blood cells","volume":"106","author":"Betz","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2024.104673_bib0015","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI110724","article-title":"Spontaneous oxygen radical generation by sickle erythrocytes","volume":"70","author":"Hebbel","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2024.104673_bib0016","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1074\/jbc.RA118.007270","article-title":"Identification and functional analyses of disease-associated P4-ATPase phospholipid flippase variants in red blood cells","volume":"294","author":"Liou","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2024.104673_bib0017","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ijlh.12223","article-title":"Rare hereditary red blood cell enzymopathies associated with hemolytic anemia - pathophysiology, clinical aspects, and laboratory diagnosis","volume":"36","author":"Koralkova","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.exphem.2024.104673_bib0018","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1124\/jpet.121.000743","article-title":"Etavopivat, a pyruvate kinase activator in red blood cells, for the treatment of sickle cell disease","volume":"380","author":"Schroeder","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.exphem.2024.104673_bib0019","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1902678","article-title":"Safety and efficacy of mitapivat in pyruvate kinase deficiency","volume":"381","author":"Grace","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2024.104673_bib0020","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/bloodadvances.2020003604","article-title":"FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice","volume":"5","author":"Shrestha","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2024.104673_bib0021","unstructured":"Schr\u00f6dinger Inc. EMPOWER. Transform drug discovery and materials research with advanced molecular modeling. 2022. Accessed February 9, 2024. Available from https:\/\/www.schrodinger.com\/platform."},{"key":"10.1016\/j.exphem.2024.104673_bib0022","series-title":"The National Academies Collection: Reports funded by National Institutes of Health. Guide for the Care and Use of Laboratory Animals","year":"2011"},{"key":"10.1016\/j.exphem.2024.104673_bib0023","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.278.5339.876","article-title":"Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease","volume":"278","author":"Paszty","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.exphem.2024.104673_bib0024","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cpdd.1058","article-title":"Safety, pharmacokinetics, and pharmacodynamics of etavopivat (FT-4202), an allosteric activator of pyruvate kinase-r, in healthy adults: a randomized, placebo-controlled, double-blind, first-in-human phase 1 trial","volume":"11","author":"Forsyth","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.exphem.2024.104673_bib0025","unstructured":"Ericsson A, Green N, Ridgefield G, et al. United States Patent Application Publication."},{"key":"10.1016\/j.exphem.2024.104673_bib0026","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.1969.tb01375.x","article-title":"A low Km phosphoenolpyruvate mutant in the Amish with red cell pyruvate kinase deficiency","volume":"17","author":"Oski","year":"1969","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2024.104673_bib0027","doi-asserted-by":"crossref","first-page":"23807","DOI":"10.1074\/jbc.M202107200","article-title":"Structure and function of human erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia","volume":"277","author":"Valentini","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2024.104673_bib0028","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1182\/blood-2016-11-753525","article-title":"AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency","volume":"130","author":"Kung","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104673_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.735543","article-title":"Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients","volume":"12","author":"Roy","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.exphem.2024.104673_bib0030","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.26923","article-title":"In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction","volume":"98","author":"D'Alessandro","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2024.104673_bib0031","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1172\/JCI105948","article-title":"Effect of altitude on oxygen binding by hemoglobin and on organic phosphate levels","volume":"47","author":"Lenfant","year":"1968","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2024.104673_bib0032","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2019.238865","article-title":"AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes","volume":"106","author":"Rab","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2024.104673_bib0033","article-title":"FT-4202 improves hematologic and hemolytic parameters in a phase 1 study of patients with sickle cell disease","author":"Clark Brown","year":"2021","journal-title":"EHA"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24005381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24005381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:22:16Z","timestamp":1736346136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X24005381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"alternative-id":["S0301472X24005381"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104673","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FT-4202, a selective pyruvate kinase R activator for sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Experimental Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104673"}}